Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up

 | Jul 30, 2019 01:04AM ET

Eli Lilly & Company (NYSE:LLY) reported second-quarter 2019 adjusted earnings per share of $1.50, which beat the Zacks Consensus Estimate of $1.46. Earnings rose 1% year over year as higher operating costs were partially offset by a lower tax rate and reduction in shares outstanding due to share repurchase.

Quarter in Detail

Lilly reported revenues of $5.64 billion, which missed the Zacks Consensus Estimate of $5.65 billion. Sales however grew 1% year over year, backed by strong demand for its newer drugs, namely Trulicity, Taltz, Jardiance, Basaglar, Olumiant and Verzenio, which compensated for lower sales of older products like Cialis.

Foreign exchange hurt sales growth by 2% in the quarter. Also, lower realized prices had a negative impact of 3% on sales. Volumes rose 6%.

New pharma products (products launched since 2014) drove 13% of volume growth and represented nearly 43% total revenues, up from 39% in the previous quarter. U.S. revenues were flat at $3.25 billion while ex-U.S. revenues rose 2% to $2.38 billion.

Among the established products, Forteo sales declined 17%to $360.8million. Alimta sales rose 4%to $577.8million. Humalog sales dropped 12% to $677.6million. Humulin sales declined 7% to $322.6 million.

Cialis sales declined 63% to $200.2million as U.S. sales were hurt by entry of generic products. Lilly lost exclusivity for Cialis in September 2018 and generic versions entered the market in the same month, resulting in rapid erosion of sales. Outside U.S. sales were also hurt by generic competition, lower realized prices and currency headwinds.

Among the new products, Trulicity generated revenues of $1.03 billion, up 32% year over year driven by higher demand in the United States and higher volumes in ex-U.S. markets, which offset the impact of lower realized prices and changes in segment mix.

Cyramza revenues were $241.8 million, up 11% year over year driven by higher sales in both U.S. and international markets. In May, Cyramza gained FDA approval for second-line liver cancer, which expanded the drug’s eligible patient population.

Jardiance sales surged 58% to $231.9 million, driven by increased demand trends within the SGLT2 class of diabetes medicines in the United States and increased volume outside the United States, which offset the negative impact of currency.

Basaglar recorded revenues of $290.7 million, up 44% year over year. In the United States, sales rose 48%, benefiting from higher demand and the impact of higher realized prices. Outside U.S. sales growth of 29% was driven by increased volume, which offset the impact of lower realized prices.

Taltz brought in sales of $353.8 million, up 61% year over year as U.S. sales gained from higher demand. Ex-U.S. sales were driven by increased volume from launches in new countries, which offset the impact of currency headwinds.

New rheumatoid arthritis drug, Olumiant generated sales of $102.4 million in the quarter backed by increased demand, compared with $82.1 million in the previous quarter. In the United States, Olumiant recorded sales of $10.7 million, higher than $6.4 million in the previous quarter.

New advanced breast cancer treatment medicine, Verzenio generated sales of $133.9 million in the quarter, which was more than $109.4 million in the previous quarter. This was because of increased demand in the United States.

The newly launched CGRP antibody, Emgality generated revenues of $34.3million in the quarter, compared with$14.2million generated in the previous quarter. In the United States, Emgality sales were $33.8 million. In June, Emgality was granted FDA approval for the preventive treatment of episodic cluster headache in adult patients.

Amgen’s (NASDAQ:AMGN) Aimovig and Teva’s (NYSE:TEVA) Ajovy were two other CGRP antibodies launched last year, which pose strong competition to Emgality.

Adjusted gross margin of 81% in the quarter expanded 120 basis points. Operating income decreased 7% year over year to $1.58 billion on higher operating expenses.

2019 Earnings Outlook Upped

Lilly raised its expectations for full-year earnings while keeping its revenue guidance intact. The earnings forecast was increased from a range of $5.60 to $5.70 per share to $5.67 to $5.77. The revenue guidance was maintained in the range of $22.0 billion - $22.5 billion.

Gross margin is still expected to be approximately 80%. Adjusted tax rate is expected to be in the range of 13%-14% versus 14%-15% expected previously.

Marketing, selling and administrative expense are expected to be in a range of $5.9 billion to $6.1 billion versus $5.7 billion to $6.0 billion expected previously. Research and development expense is still expected to be in the range of $5.5 billion to $5.7 billion.

Positive Overall Survival Data from MONARCH 2 study

In a separate press release, Lilly announced that treatment with Verzenio in combination with fulvestrant led to a statistically significant improvement in overall survival (OS) in the phase III MONARCH 2 study. The study evaluated Verzenio plus fulvestrant in HR+, HER2- advanced breast cancer patients who experienced disease progression following endocrine therapy. Please note that Verzenio plus fulvestrant is already approved for the above patient population on the basis of progression-free survival data from the same study. Lilly will now look to get approval for OS data from the study to be included on the drug’s label.

Our Take

Lilly beat estimates for second-quarter earnings but missed the same for sales by a whisker. The stock was up around 1% in pre-market trading on the second-quarter earnings beat and raised earnings guidance for the full year. However, so far this year, shares of Lilly have declined 6% against the Zacks Investment Research

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes